Moderna (MRNA) Change in Accured Expenses (2018 - 2026)

Moderna has reported Change in Accured Expenses for 9 years, with the latest figure at $11.0 million in Q2 2026.

• Change in Accured Expenses for Q2 2026 came in at $11.0 million, up 178.57% year-over-year; the trailing twelve-month figure through Jun 2026 was $864.0 million (up 373.42% YoY), and the FY2025 annual result was -$6.0 million, up 98.44% from the prior year.
• Change in Accured Expenses declined to $11.0 million in Q2 2026, from $464.0 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $696.0 million in Q3 2023 and troughed at -$1.1 billion in Q4 2022.
• A 5-year average of -$55.3 million and a median of $20.5 million in 2024 frame the typical range for Change in Accured Expenses.
• The largest YoY upside for Change in Accured Expenses was 1320.41% in 2023 against a maximum downside of 534.21% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at -$1.1 billion in 2022, then jumped by 63.16% to -$403.0 million in 2023, then jumped by 107.44% to $30.0 million in 2024, then jumped by 533.33% to $190.0 million in 2025, then sank by 94.21% to $11.0 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $11.0 million in Q2 2026, $464.0 million in Q1 2026, and $190.0 million in Q4 2025.